welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Kanneboyina Nagaraju, PhD, DVM

Founding Chair
School of Pharmacy and Pharmaceutical Sciences
Binghamton University
State University of New York
PO Box 6000
Binghamton, New York, United States

Kanneboyina Nagaraju received his bachelor’s degree in veterinary medicine from the College of Veterinary Sciences, Tirupati, India, in 1986; his master’s degree in veterinary immunology from the prestigious Indian Veterinary Research Institute, Izatnagar, in 1989; and his PhD in immunology from Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India in 1995. Immediately after completing his PhD, he came to the United States to do a postdoctoral fellowship at the National Institutes of Health (NIH) in Bethesda, Maryland.

After completing this fellowship in 1999, he became a tenure-track assistant professor in the Division of Rheumatology, Department of Medicine of the Johns Hopkins University School of Medicine in Baltimore, Md. In 2005, he joined the Research Center of Genetic Medicine, Children’s Research Institute of the Children’s National Medical Center (CNMC) and was appointed an associate professor of pediatrics at the George Washington University School of Medicine and Health Sciences (GWSMHS) in Washington, DC.

Nagaraju has co-founded two biotech companies, ReveraGen BioPharma, a biotech company focused on developing dissociated glucocorticoid therapies for inflammatory diseases including muscular dystrophy, and AGADA BioSciences, a preclinical drug screening and phenotyping company to facilitate development of therapeutics for rare neuromuscular diseases.

He currently serves as a member of medical and scientific advisory boards of the Myositis Association, Muscular Dystrophy Association and Cure Duchenne, as well as he is one of the founding core preclinical experts on the TREAT-NMD Advisory Committee for Therapeutics.


Representative Publications:

Vamorolone Trial in Duchenne Muscular Dystrophy Shows Dose-Related Improvement of Muscle Function

Vamorolone, a Dissociative Steroidal Compound, Reduces Collagen Antibody-Induced Joint Damage and Inflammation When Administered After Disease Onset

Orthogonal Analysis of Dystrophin Protein and mRNA as a Surrogate Outcome for Drug Development

Discovery of Potential Urine-Accessible Metabolite Biomarkers Associated With Muscle Disease and Corticosteroid Response in the Mdx Mouse Model for Duchenne

Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy